Serum sickness following rituximab therapy in multiple sclerosis.

Abstract

Consider serum sickness and avoid further infusions in patients who develop fever, arthralgia, and elevated inflammation parameters around 10 days after treatment with chimeric monoclonal antibodies such as rituximab.